Nivolumab is an immune checkpoint inhibitor (ICI) that facilitates T cell activation, which results in great efficacy in melanoma (1, 2). The dosage originally approved worldwide was 2-3 mg/kg or… Click to show full abstract
Nivolumab is an immune checkpoint inhibitor (ICI) that facilitates T cell activation, which results in great efficacy in melanoma (1, 2). The dosage originally approved worldwide was 2-3 mg/kg or 240 mg/body every two-three weeks (LOW-dose regimen). In 2020, a new dosage regimen of 480 mg/body of nivolumab every four weeks (HIGH-dose regimen) was approved in Japan.
               
Click one of the above tabs to view related content.